Positive results from the Phase III BASIS study show the potential of Pfizer’s (NYSE: PFE) novel hemophilia therapy marstacimab.
The US Food and Drug Administration (FDA) Fast Track-designated antibody is being developed for people with hemophilia A or B, without inhibitors to Factor VIII or Factor IX.
The BASIS study met its primary endpoints, generating a statically-significant and clinically-meaningful effect when given subcutaneously on a weekly basis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze